Gene patent ruling leaves unanswered questions

A seemingly decisive Supreme Court ruling against gene patents in June left a lot of issues unsettled, and the industry can expect much more litigation to come, experts say.

The decision invalidated patents claimed by Myriad Genetics against rival Ambry Genetics on the use of naturally occurring DNA sequences in tests for the risk of breast cancer. Yet on July 9, Myriad filed another lawsuit against Ambry and Gene by Gene, citing other patent violations

The Myriad case marks the beginning of a cultural shift in how biotech patents are viewed, to take into account public needs, said University of Michigan researcher Shobita Parthasarathy. But other decisions, and a change of attitude from the U.S. Patent and Trademark Office, will be needed to confirm that shift.

Read the full, original story here: Gene patent ruling leaves unanswered questions

Outbreak Daily Digest
Biotech Facts & Fallacies
Talking Biotech
Genetics Unzipped
Infographic: The evolutionary history of the COVID-19 coronavirus

Infographic: The evolutionary history of the COVID-19 coronavirus

Reuters analysed over 185,000 genome samples from the Global Initiative on Sharing All influenza Data (GISAID), the largest database of ...

Environmental Working Group: EWG challenges safety of GMOs, food pesticide residues

Known by some as the "Environmental Worrying Group," EWG lobbies ...
m hansen

Michael Hansen: Architect of Consumers Union ongoing anti-GMO campaign

Michael K. Hansen (born 1956) is thought by critics to be ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend